Under construction – not a live service
Sign in
Taking people in ChinaPhase 2

Tests interferon-alpha to prevent relapse after stem cell transplant

Tests interferon-alpha to prevent relapse in people with TP53-mutated myeloid cancers after transplant.

Plain-language title generated from the registry record
Registry title: Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT

Key facts

Where
Beijing, ChinaSee the site
Phase
Phase 2

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 12-65 with MDS or AML with a TP53 mutation, who had a first stem-cell transplant from a donor and tested MRD-negative within 2 months after it. It tests interferon-α to lower the chance of relapse.

Age
12-65 years
Sex
Men and women
Disease stage
Myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with a TP53 mutation, any remission status. MRD negative by flow cytometry within 2 months after the first allogeneic stem-cell transplant.
Earlier treatment
Must have had a first allogeneic hematopoietic stem cell transplant. Must have no history of severe graft-versus-host disease (GVHD) or uncontrolled GVHD.
Biomarker or test result
TP53 mutation. Minimal residual disease (MRD) negative by flow cytometry within 2 months after transplant.

Main reasons for not taking part

  • Severe heart, kidney or liver problems
  • Other cancer that needs treatment
  • Severe acute allergic reaction
  • Uncontrolled severe life-threatening infection
  • Taking part in other clinical trials

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 12 and 65 years old?

Source: NCT06130579, who can take part

Where in China

  • Deparment of Hematology, Peking University People's HospitalBeijing, ChinaContact: Xiaojun Huang, doctorTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Peking University People's Hospital
Trial code
NCT06130579
Record updated
3 June 2025
Original description
To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) by flow cytometry within 2 months after allogeneic hematopoietic stem cell transplantation. To explore the efficacy of interferon-α in reducing the relapse rate of AML/MDS patients with TP53 mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT).Read full original descriptionShow less

Interferon-α for Preventing Relapse in TP53+ Myeloid Malignancy Post Allo-HSCT

To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) by flow cytometry within 2 months after allogeneic hematopoietic stem cell transplantation. To explore the efficacy of interferon-α in reducing the relapse rate of AML/MDS patients with TP53 mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Inclusion: Myelodysplastic syndrome (MDS) diagnosed according to the 2022 International Consensus Classification of Myeloid Neoplasms and Acute Leukemia (2022ICC) criteria, acute myeloid leukemia (AML) with TP53 mutation (unrestricted remission status), minimal residual disease (MRD) monitored by flow cytometry within 2 months after receiving the first allogeneic hematopoietic stem cell transplantation Negative patients; Male or female, aged 12-65 years; Karnofsky score >60, estimated survival time >3 months; No history of severe graft-versus-host disease (GVHD), uncontrolled GVHD, or severe systemic organ dysfunction:; Absolute neutrophil count (ANC) greater than 0.5×109/L; Creatinine < 1.5mg/dL; Cardiac ejection index >55%; Signed informed consent.

Exclusion: severe cardiac, renal, or liver dysfunction; combined with other malignant tumors requiring treatment; inability to understand or adhere to the study protocol due to clinical symptoms of brain dysfunction or severe mental illness; clinically uncontrolled severe life-threatening infections; patients who are unable to complete the necessary treatment plan and follow-up observation; patients with severe acute anaphylaxis; patients enrolled in other clinical trials; other reasons considered by the investigator to be inappropriate for clinical trial participants.

ClinicalTrials.gov NCT06130579